Sub-tenon’s injection of recombinant prourokinase (Hemase) combined with intravitreal injection of a neoangiogenesis inhibitor (Eylea) in the treatment of massive subretinal hemorrhage in neovascular age-related macular degeneration. A clinical case
https://doi.org/10.21516/2072-0076-2025-18-4-132-138
Abstract
This paper describes a clinical case of neovascular age-related macular degeneration complicated by subretinal hemorrhage and analyzes the effectiveness of minimally invasive combination treatment, which included a sub-Tenon injection of recombinant prourokinase (Hemase) simultaneously with an intravitreal injection of a neoangiogenesis inhibitor (Eylea). This treatment resulted in significant positive results within a short period of time (1 month), including complete hemorrhage resorption and improved visual acuity, which made it possible to postpone or completely avoid open surgery.
About the Authors
M. T. Mikailova
Dagestan Center for Eye Microsurgery
Russian Federation
Russian Federation
Maysarat T. Mikailova — ophthalmologist, department of retinal pathology and laser surgery
12/2, M. Khalilova St., Kaspiysk, Republic of Dagestan, 368300
S. I. Zakieva
Dagestan Center for Eye Microsurgery;
Dagestan State Medical University
Russian Federation
Russian Federation
Savat I. Zakieva — Cand. of Med. Sci., head of the department of retinal pathology and laser surgery, Dagestan Center for Eye Microsurgery, associate professor of chair of eye diseases, Dagestan State Medical University
12/2, M. Khalilova St., Kaspiysk, Republic of Dagestan, 368300,
1 Lenin Square, Makhachkala, Republic of Dagestan, 367000
M. M. Magomedova
Dagestan Center for Eye Microsurgery;
Dagestan State Medical University
Russian Federation
Russian Federation
Maryam M. Magomedova — PhD student, Dagestan Center for Eye Microsurgery, assistant of the chair of eye diseases, Dagestan State Medical University
12/2, M. Khalilova St., Kaspiysk, Republic of Dagestan, 368300,
1 Lenin Square, Makhachkala, Republic of Dagestan, 367000
References
1. Budzinskaya M.V., Vorobyova M.V., Kiseleva T.N., Lagutina Yu.M., Polunin G.S. Modern approaches to the treatment and prevention of age-related macular degeneration. Clinical ophthalmology. 2007; 8 (2): 78–82 (In Russ.)
2. Ermakova N.A., Rabdanova O.C. The main etiological factors and pathogenetic mechanisms of age-related macular degeneration. Clinical ophthalmology. 2007; 8 (3): 125–8 (In Russ.).
3. Nesterov A.P., Basinsky S.N. A new method of introducing drugs into the posterior part of the tenon space. Vestnik oftal’mologii. 1991; 5: 49–51 (In Russ.).
4. Grzybowski A, Told R, Sacu S, et al. 2018 Update on intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica. 2018; 239 (4): 181–93. doi: 10.1159/000486145
5. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004 Oct; 24 (5): 676–98. doi: 10.1097/00006982-200410000-00002
6. Chang W, Chung M. Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection. Eur J Ophthalmol. 2007 Sep-Oct; 17 (5): 776–9. doi: 10.1177/112067210701700514
7. Sharei V, Höhn F, Köhler T, et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010 Jan-Feb; 20 (1): 174–9. doi: 10.1177/112067211002000124
8. Hollands H, Wong J, Bruen R. Short-tern intraocular changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007; 42: 807–11. doi.org/10.3129/i07-172
9. Sniegowski M, Mandava N, Kahook M. Sustained intraocular pressure elevation after intravitreal injection of Bevacizumab and Ranibizumab associated with trabeculitis. Open Ophthalmol. 2016; 10: 32–5. doi.org/10.2174/1874364101004010028
10. Hillenkamp J, Surguch V, Framme C, et al. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2010 Jan; 248 (1): 5–11. doi: 10.1007/s00417-009-1158-7
11. Ovchinnikova A.D., Mironov A.V., Dulgieru T.O. Surgical treatment of massive submacular hemorrhages in the wet form of age-related macular degeneration with automated subretinal injection. Ophthalmosurgery. 2020; 4: 43–9 (In Russ.). https://doi.org/10.25276/0235-4160-2020-4-43-49
Review
For citations:
Mikailova M.T., Zakieva S.I., Magomedova M.M. Sub-tenon’s injection of recombinant prourokinase (Hemase) combined with intravitreal injection of a neoangiogenesis inhibitor (Eylea) in the treatment of massive subretinal hemorrhage in neovascular age-related macular degeneration. A clinical case. Russian Ophthalmological Journal. 2025;18(4):132-138. (In Russ.) https://doi.org/10.21516/2072-0076-2025-18-4-132-138
Views:
22
Email this article 